Loading chat...
IN SB0371
Bill
Status
1/4/2018
Primary Sponsor
Blake Doriot
Click for details
AI Summary
SB 371 Summary
-
Expands the definition of "industrial hemp" to explicitly include resins from the Cannabis sativa plant, with THC content not exceeding 0.3% by dry weight.
-
Permits sale of topical and ingestible hemp-derived commodities and products if manufacturers register with the state seed commissioner, pay registration fees, and products pass independent laboratory testing for THC content and contaminants.
-
Requires the state seed commissioner to maintain a public website listing compliant hemp-derived products and to conduct random testing, with authority to suspend registrations for non-compliant items.
-
Excludes hemp-derived products containing no more than 0.3% THC from definitions of "controlled substance," "hashish," "hash oil," and "marijuana" under criminal law, provided they meet testing and labeling requirements.
-
Expands the cannabidiol registry to include individuals diagnosed with ALS, Crohn's disease, mitochondrial disease, multiple sclerosis, Parkinson's disease, and sickle cell disease, with registration fees of up to $50 initial and $25 renewal.
Legislative Description
Industrial hemp commodities and products. Specifies that the definition of "industrial hemp" includes the resins of the Cannabis sativa plant. Allows a person to sell topical and ingestible commodities and products that are derived from industrial hemp if certain conditions are met. Requires the commodities and products to be tested. Requires the state seed commissioner to maintain an Internet web site that lists the topical and ingestible commodities and products that comply with the testing, registration, and labeling requirements. Allows individuals with certain medical conditions that have been diagnosed by a physician to qualify to be on the cannabidiol registry.
Last Action
First reading: referred to Committee on Corrections and Criminal Law
1/4/2018